Edwards Lifesciences reports 8% Q1 2025 sales growth to $1.41B, driven by TAVR & TMTT. Discover regulatory catalysts & future growth insights.

Edwards Lifesciences raised its 2025 sales forecast on Wednesday after a quarterly beat, driven by robust demand for its artificial heart valves and other medical equipment.

Edwards Lifesciences (NYSE: EW) shares stayed put after hours today on first-quarter results that beat Wall Street ...

Discover key insights from Vertiv's Q1 2025 earnings call, highlighting 25% organic sales growth, tariff mitigation strategies, and updated 2025 ...

E.l.f. Beauty Inc. management misdirected that demand was high and inflated inventory levels were fine before its stock’s ...

Avery Dennison (AVY) reported $2.15 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 0.1%. EPS of $2.30 for the same period compares to $2.29 a year ago.

Elevator maker Otis raised its full-year revenue forecast on Wednesday, after beating first-quarter profit estimates on sustained demand for its maintenance and modernization services.